The rapid expansion of cell and gene therapies is reshaping modern medicine.
𝗯𝗶𝗼𝗠ér𝗶𝗲𝘂𝘅’𝘀 𝗮𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻 𝗼𝗳 𝗔𝗰𝗰𝗲𝗹𝗹𝗶𝘅 strengthens our Group’s capacity to support the development of advanced therapies with highperformance quality control tools. For Institut Mérieux, this strategic move illustrates how our companies contribute to therapeutic progress, ultimately helping ensure that these innovations reach patients safely and reliably.
To learn more about this acquisition: click here.